MiMedx is in trou­ble, again; Pfiz­er's Avastin biosim­i­lar wins FDA ap­proval

→ The con­tro­ver­sial MiMedx has dug it­self a deep­er hole. Se­nior of­fi­cials at the wound care com­pa­ny, which has long been crit­i­cized for its busi­ness …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.